Veit Bücklein, Dr Med, on Looking Closer Into Differences in Response, Hematotoxicity After CAR T
January 9th 2024The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed further research his group is conducting with cell therapy.
Continued Research on Exa-cel and Lovo-cel Remains Important After FDA Approval
January 9th 2024Alexis Thompson, MD, MPH, the chief of hematology at Children’s Hospital of Philadelphia, discussed the need to determine whether the recently approved sickle cell disease gene therapies could benefit younger patients.
Gregory W. Roloff, MD, on Confirming Durable Efficacy of Brexu-Cel and Maintenance Therapy in B-ALL
January 7th 2024The chief hematology/oncology fellow at University of Chicago discussed real-world experience data and new analyses of patients with B-cell acute lymphoblastic leukemia treated with brexu-cel.
Aliya Rashid, DO, MPH, on The Significant Minority of Female Authorship in Pivotal CAR T-Cell Trials
January 5th 2024The internal medicine resident physician at University of Kansas Medical Center discussed research conducted into gender authorship rates of 13 pivotal trials published between 2017 and 2022.